Cambridge University: Timeline of key events

Mouseover the event title for a more detailed description of the event (if available). To search for particular terms in the description of the event enter the term in the box below 'Event' on the table and press 'enter'. Alternatively use the dropdown lists to filter by Person, Place or Science. Click here to clear the filter.

UK scientists modified 41 embryos shortly after fertilisation. N.M.E. Fogarty et al, 'Genome editing reveals a role for OCT4 in human embryogenesis', Nature, doi:10.1038/nature240332017-09-20T00:00:00+0000The patient received a stem-cell transplant that replaced their white blood cells with HIV-resistant versions. The cells were taken from a donor who had two copies of a mutation in the CCR5 gene that confers resistance to HIV infection. The CCR5 gene codes for a receptor on white blood cells involved in the body's immune response. HIV normally binds to these receptors and attacks the cell. By removing the gene the receptors stop working normally. The patient was given the treatment as part of therapy for blood cancer. He was able to stop taking antiretroviral drugs after 16 months, and 18 months later had no sign of the virus. The research was published in RK Gupta, et al, Nature (2019), DOI 10.1038/s41586-019-1027-42019-03-05T00:00:00+0000
Date Event People Places Sciences
Sep 2017DNA of human embryos edited using CRISPR-Cas9 to study cause of infertilityFogarty, McCarthy, Snijders, Powell, Kubikova, Blakeley, Lea, Elder, Wamaitha, Kim, Maciulyte, Kleinjung, Kim, Wells, Vallier, Bertero, Turner, NiakanFrancis Crick Instiitute, Cambridge University, Oxford University, Seoul National UniversityCRISPR-Cas9, Gene editing, Reproduction
5 Mar 2019Second patient reported free of HIV after receiving stem-cell therapyGuptaUniversity of CambridgeStem cells, Gene therapy

Sep 2017

DNA of human embryos edited using CRISPR-Cas9 to study cause of infertility

5 Mar 2019

Second patient reported free of HIV after receiving stem-cell therapy

Respond to or comment on this page on our feeds on Facebook, Instagram or Twitter.